Why Idenix Pharmaceuticals, Supernus Pharmaceuticals, and Westmoreland Coal Are Today's 3 Best Stock
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
This Christmas spirit was in full swing on Wall Street today with a double-dose of poor economic data hitting the tape and the broad-based S&P 500 shrugging it off and hitting another fresh all-time high anyway.
First, the weekly report from the Mortgage Brokers Association showed that weekly loan originations dropped 6.3% from the previous week. This figure is very sensitive to interest rates, and rates recently bounced a bit, so it's not a huge surprise. I would point out, though, that U.S. consumers have been spoiled with low interest rates for years, and their insistence on waiting for even lower rates may turn out to be a poor decision for them and the homebuilding sector.
Along those same lines, new home sales for November fell 10,000 to a seasonally adjusted annual rate of 464,000. The 2.1% month-over-month drop was actually a bit less than economists expected, but it nonetheless points to an ongoing weakening in the housing market.
By day's end, the S&P 500 jumped higher by another 5.33 points (0.29%) to close at 1,833.32. The index is now up approximately 27% year to date.
Leading all stocks higher today, despite a lack of market-specific news, was hepatitis-C-focused therapy developer Idenix Pharmaceuticals , which jumped by 18.2% on this shortened day of trading. Despite its recent pipeline woes and the ongoing clinical hold of IDX20963, which is anticipated to be a game-changing experimental compound for Idenix, the potential for royalty compensation derived from a patent dispute with Gilead Sciences over the recently approved hepatitis-C medication, Sovaldi, could be today's upside culprit. As for me, I prefer to the let the pipelines, not the courtrooms, do the talking, and Idenix has been practically put on mute by its competitors up until now.
Sticking within the biotech sector, Supernus Pharmaceuticals added 13.2% as a continuation of a move from yesterday's approval by the Food and Drug Administration of Orenitram for the treatment of pulmonary arterial hypertension. The drug, which will benefit United Therapeutics the most, as we saw from yesterday's 30% romp higher, also allows Supernus to collect milestone and single-digit royalties on worldwide sales of the drug. Specifically, Supernus could be entitled to a $2 million royalty payment for the FDA approval of the drug. While this is good news, I might hold my cheering until we see how well Orenitram sells.
Finally, shares of thermal coal miner Westmoreland Coal shot higher by 11.2% after announcing the acquisition of Sherritt International's Prairie and Mountain coal mining operations for $435 million. The deal includes seven thermal coal mines and a 50% interest in an activated carbon plant and char production facility in Canada. In addition, the deal is expected to immediately be cash flow-positive for Westmoreland Coal. While I certainly appreciate Westmoreland's aggressiveness, I'm still a bit concerned about the possibility for integration issues as well as the ongoing weakness in thermal coal pricing. I'd rather take a back seat here for the time being and see how this situation plays out.
Tired of not seeing your holdings among the top gainers? Perhaps you aren't thinking far enough outside the box!
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
The article Why Idenix Pharmaceuticals, Supernus Pharmaceuticals, and Westmoreland Coal Are Today's 3 Best Stocks originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong . The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.